Figure 1From: Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study Rate of withdrawal of patients over the 3-years duration of the study by baseline post-bronchodilator FEV 1 % predicted.Back to article page